Reuters, 9 Jun 2009, Nopporn Wong-Anan
SINGAPORE, June 9 (Reuters) - GlaxoSmithKlyne (GSK.L) plans to start producing vaccines from 2011 in Singapore to fight pneumonia-causing bacteria, which kills more than 1 million children each year around the world.
The world's second biggest drugmaker opened a S$600 million ($411 million) plant in the city-state on Tuesday, its second global site to manufacture the pneumococcal conjugate vaccine after Belgium.
Read More
Related News:
Glaxosmithkline Opens Largest Vaccine Plant In Asia - Bernama.com
